Licensing · Global (LMICs) · Announced 21 Jan 2026
Galenicum → Lupin
Galenicum licensed its generic semaglutide injection to Lupin for 23 countries, including Southeast Asian markets; Galenicum develops, makes and supplies, while Lupin registers and sells.
Parties: Galenicum (Spain) → Lupin (India)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- 23 countries (not listed), including markets in Canada, Europe, Southeast Asia and Latin America
- Therapeutic area
- Metabolic / Diabetes
- Asset
- Semaglutide
- Announced
- 21 Jan 2026
Our analysis
Why this matters
On 21 January 2026, Lupin and Spain's Galenicum signed a licence and supply agreement for generic semaglutide injection in 23 countries. Galenicum is responsible for development, manufacturing and supply; Lupin, through its subsidiary Lupin Atlantis Holdings, handles regulatory submissions, approvals, commercialisation and distribution. The release does not list the 23 countries but names markets in Canada, Europe, Southeast Asia and Latin America. Semaglutide is a GLP-1 receptor agonist used in type 2 diabetes and, in some formulations, weight management. No financial terms were disclosed.
Semaglutide patents begin to expire in several markets from 2026, opening a large generic opportunity.
The full analysis is free to read with a work email on this page.
Source: Lupin press release